Biotech Values

[DewDiligence]

Re: GTCB

>>I don't see where the EMEA trial actual results were discussed (I do see where there were 2 DVTs - was that the only end-point ?)<<

Avoidance of DVT was indeed the efficacy endpoint in the European trial. The two cases were only suspected DVT based on ultrasound scans – not actual clinical cases of DVT.

>>Also, what is the historical rate of DVTs (or other endpoint events or occurrence) - meaning how does the "control arm" typically fare?<<

For individuals with hereditary AT deficiency undergoing surgery or childbirth without antithrombin augmentation, the rate of clinical DVT is 30%+.